newsfilter
← Latest News
GlobeNewswire·

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

  • InspireMD amended Series J & K warrants to align exercise triggers with anticipated FDA approval of CGuard Prime 80 cm in Q4 2026
  • Approximately 4.8 million Series J shares & 9.5 million Series K shares are subject to the amendments
  • New exercise price set at $0.7674 per share for 50% of Series J shares & all Series K shares
  • New termination date established as May 15, 2028 or 20 trading days post-FDA approval announcement, whichever is earlier
  • Remaining 50% of Series J shares retain original terms with termination triggers linked to SwitchGuard system approval
  • No additional warrants or shares were issued as part of the amendments
  • Proceeds from full exercise combined with existing cash will fund the commercial launch of CGuard Prime 80 cm
  • CGuard Prime 80 cm targets TCAR procedures, expanding the addressable market to over 35,000 annual US procedures
  • Phase III CGUARDIANS II study data showed 100% acute device success & zero major adverse events in 36 patients